A5070953014- Attention Deficit Hyperactivity Disorder
- Child and Adolescent Psychosocial and Emotional Development
- Viral Infections and Outbreaks Research
- Disaster Response and Management
- Pharmaceutical studies and practices
- Children's Physical and Motor Development
- Bipolar Disorder and Treatment
- Treatment of Major Depression
- Maternal Mental Health During Pregnancy and Postpartum
- Neural and Behavioral Psychology Studies
- Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Functional Brain Connectivity Studies
- Adolescent and Pediatric Healthcare
- Autism Spectrum Disorder Research
- Disaster Management and Resilience
- Bacillus and Francisella bacterial research
- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
- COVID-19 and healthcare impacts
- Perfectionism, Procrastination, Anxiety Studies
- Behavioral and Psychological Studies
- Pharmacological Effects and Toxicity Studies
- Obsessive-Compulsive Spectrum Disorders
- Ethics in Clinical Research
- Health Policy Implementation Science
University of Nebraska Medical Center
2015-2024
Nebraska Medical Center
2002-2024
Emory University Hospital
2017
Chancellor University
2015
Eli Lilly (United States)
2005-2009
Duke University Hospital
2005-2009
Duke Medical Center
2005-2009
University of Nebraska–Lincoln
2006-2009
National Institute of Mental Health
2007-2009
Icahn School of Medicine at Mount Sinai
2009
OBJECTIVE: The authors assessed the efficacy of once-daily atomoxetine administration in treatment children and adolescents with attention deficit hyperactivity disorder (ADHD). METHOD: In a double-blind study, ADHD (N=171, age range=6–16 years) were randomly assigned to receive 6 weeks either (administered once daily) or placebo. RESULTS: Outcomes among atomoxetine-treated patients superior those placebo group as by investigator, parent, teacher ratings. effect size (0.71) was similar...
Objective: Response to atomoxetine, a nonstimulant norepinephrine-specific reuptake inhibitor, was compared with the effect of osmotic-release oral methylphenidate, long-acting methylphenidate preparation, in patients attention deficit hyperactivity disorder (ADHD). Method: In large placebo-controlled, double-blind study, ages 6–16 ADHD, any subtype, were randomly assigned receive 0.8–1.8 mg/kg per day atomoxetine (N=222), 18–54 mg/day osmotically released (N=220), or placebo (N=74) for 6...
<h3>Importance</h3> Myocarditis is a leading cause of sudden death in competitive athletes. Myocardial inflammation known to occur with SARS-CoV-2. Different screening approaches for detection myocarditis have been reported. The Big Ten Conference requires comprehensive cardiac testing including magnetic resonance (CMR) imaging all athletes COVID-19, allowing comparison approaches. <h3>Objective</h3> To determine the prevalence COVID-19 and compare strategies safe return play. <h3>Design,...
Background. The current West Africa Ebola virus disease (EVD) outbreak has resulted in multiple individuals being medically evacuated to other countries for clinical management.
Article AbstractBackground: Atomoxetine is a nonstimulant drug being studied for the treatment of attention-deficit/hyperactivity disorder (ADHD). highly specific inhibitor presynaptic norepinephrine transporter with minimal affinity other noradrenergic receptors or neurotransmitter transporters receptors. Results 2 proof-of-concept studies are reported that tested hypothesis selective uptake would be effective ADHD in school-aged children. Method: Two identical 12-week, stratified,...
Major depressive disorder in adolescents is common and impairing. Efficacious treatments have been developed, but little known about longer-term outcomes, including recurrence.To determine whether who responded to short-term or received the most efficacious treatment would lower recurrence rates, identify predictors of recovery recurrence.Naturalistic follow-up study.Twelve academic sites United States.One hundred ninety-six (86 males 110 females) randomized 1 4 interventions (fluoxetine...
Article AbstractObjective: The Treatment for Adolescents with Depression Study (TADS) database was analyzed to determine whether suicidal events (attempts and ideation) occurred early in treatment, could be predicted by severity of depression or other clinical characteristics, were preceded deterioration symptoms increased irritability, akathisia, sleep disruption, mania.Method: TADS a 36-week randomized, controlled trial pharmacologic psychotherapeutic treatments involving 439 youths major...
Caring for highly infectious patients in biocontainment units is a new phenomenon, and little known about the behavioral health of workers this setting. This qualitative study exploring unique experiences involved care with Ebola virus disease (EVD) at Nebraska Medicine during 2014 outbreak. Twenty-one in-depth interviews were conducted focused on topics personal memories, interpersonal experiences, stress response, patient management. Five themes identified: (1) positive emotional while...
<h3>Background</h3> Despite the persistence of attention-deficit/hyperactivity disorder (ADHD) into adolescence, little is known about efficacy and tolerability stimulant medications in this age group. <h3>Objective</h3> To report results a multisite controlled study among adolescents with ADHD evaluating osmotic-release oral system (OROS) methylphenidate. <h3>Design</h3> Adolescents (N = 220) having confirmed<i>Diagnostic Statistical Manual Mental Disorders, Fourth Edition</i>diagnosis...
Objective. Modafinil, which is structurally and pharmacologically different from other agents that are used for the treatment of children with attention-deficit/hyperactivity disorder (ADHD), selectively activates cortex has low potential abuse. Initial studies use modafinil to treat ADHD showed significant improvements in core symptoms disorder, namely inattention, hyperactivity, impulsivity. This study evaluated a new formulation (modafinil film–coated tablets) adolescents ADHD. Methods....
Objective: The Treatment for Adolescents With Depression Study (TADS) evaluates the effectiveness of fluoxetine, cognitive-behavioral therapy (CBT), and their combination in adolescents with major depressive disorder. authors report outcomes across a 1-year naturalistic follow-up period. Method: randomized, controlled trial was conducted 13 academic community sites United States. Stages I, II, III consisted 12, 6, 18 weeks acute, consolidation, continuation treatment, respectively. Following...
The review presents pediatric adverse drug events from a historical perspective and focuses on selected safety issues associated with off-label use of medications for the psychiatric treatment youth. Clinical monitoring procedures major psychotropic classes are reviewed. Prior studies suggest that systematic is warranted so as to both minimize risk unexpected exposures ineffective treatments. trials establish efficacy drugs currently being used in population needed. In meantime, clinicians...